Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations

Department of Medicine, Methodist Hospital, Houston, Texas.

Mean plasma lipid values in 100 patients who survived greater than 3 months after heart transplantation increased significantly at 3 months over pretransplantation values: total cholesterol from 168 +/- 7 to 234 +/- 7 mg/dl, low density lipoprotein (LDL) cholesterol from 111 +/- 6 to 148 +/- 6 mg/dl, high density lipoprotein (HDL) cholesterol from 34 +/- 1 to 47 +/- 1 mg/dl and triglycerides from 107 +/- 6 to 195 +/- 10 mg/dl. There were no significant increases after this time. The LDL cholesterol values reamined greater than or equal to 130 mg/dl in 64% of patients and triglyceride values remained greater than or equal to 200 mg/dl in 41% of patients 6 months after postoperative dietary instructions. Beginning in 1985, select patients whose total cholesterol values remained greater than 300 mg/dl despite 6 months of dietary intervention were treated with lovastatin given alone in a high dose (40 to 80 mg/day) or in combination with another hypolipidemic agent. Four of the five patients so treated developed rhabdomyolysis; two of the four had acute renal failure. Beginning in 1988, a second protocol--lovastatin at 20 mg/day as monotherapy--was used in patients who despite dietary intervention had total cholesterol greater than 240 mg/dl (mean follow-up 13 months). In the 15 patients so treated, mean total cholesterol decreased from 299 +/- 10 mg/dl before treatment with lovastatin to 235 +/- 9 mg/dl during treatment (21% reduction, p less than 0.001) and mean LDL cholesterol was reduced from a baseline value of 190 +/- 10 to 132 +/- 12 mg/dl during treatment (31% reduction, p less than 0.001). In this study, lovastatin at a dose of less than or equal to 20 mg/day as monotherapy was a well tolerated, effective treatment for hyperlipidemia after heart transplantation. It did not result in rhabdomyolysis and required no alteration in immunosuppressive therapy. However, the dose should not exceed 20 mg/day and combination therapy with either gemfibrozil or nicotinic acid should be avoided, even if the target LDL cholesterol value is not reached.

This article has been cited by other articles:

				N. Z. Sulemanjee, R. Merla, S. D. Lick, S. M. Aunon, M. Taylor, M. Manson, L. S.C. Czer, and E. R. Schwarz The First Year Post-Heart Transplantation: Use of Immunosuppressive Drugs and Early Complications Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 13 - 31. [Abstract] [PDF]

				J. Lindenfeld, R. L. Page II, R. Zolty, S. F. Shakar, M. Levi, B. Lowes, E. E. Wolfel, and G. G. Miller Drug Therapy in the Heart Transplant Recipient: Part III: Common Medical Problems Circulation, January 4, 2005; 111(1): 113 - 117. [Full Text] [PDF]

				S. de Denus, A. Al-Jazairi, E. Loh, M. Jessup, E. J Stanek, and S. A Spinler Dyslipidemias and HMG-CoA Reductase Inhibitor Prescription in Heart Transplant Recipients Ann. Pharmacother., July 1, 2004; 38(7): 1136 - 1141. [Abstract] [Full Text] [PDF]

				C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. Marz, J. P. D. Reckless, and E. A. Stein Risk for Myopathy With Statin Therapy in High-Risk Patients Arch Intern Med, March 10, 2003; 163(5): 553 - 564. [Abstract] [Full Text] [PDF]

				J. C. Fang, S. Kinlay, D. Behrendt, H. Hikita, J. L. Witztum, A. P. Selwyn, and P. Ganz Circulating Autoantibodies to Oxidized LDL Correlate With Impaired Coronary Endothelial Function After Cardiac Transplantation Arterioscler Thromb Vasc Biol, December 1, 2002; 22(12): 2044 - 2048. [Abstract] [Full Text] [PDF]

				J.-W. Park, R. Siekmeier, P. Lattke, M. Merz, C. Mix, S. Schuiler, and W. Jaross Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 351 - 361. [Abstract] [PDF]

				M. Weis, S. Pehlivanli, B. M. Meiser, and W. von Scheidt Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation J. Am. Coll. Cardiol., September 1, 2001; 38(3): 814 - 818. [Abstract] [Full Text] [PDF]

				F. D. Knollmann, M. Hummel, R. Hetzer, and R. Felix CT of Heart Transplant Recipients: Spectrum of Disease RadioGraphics, November 1, 2000; 20(6): 1637 - 1648. [Abstract] [Full Text] [PDF]

				M. Bottorff and P. Hansten Long-term Safety of Hepatic Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors: The Role of Metabolism--Monograph for Physicians Arch Intern Med, August 14, 2000; 160(15): 2273 - 2280. [Full Text] [PDF]

				D. H. Walter, J. Haendeler, J. Galle, A. M. Zeiher, and S. Dimmeler Cyclosporin A Inhibits Apoptosis of Human Endothelial Cells by Preventing Release of Cytochrome C From Mitochondria Circulation, September 22, 1998; 98(12): 1153 - 1157. [Abstract] [Full Text] [PDF]

				M. Carrier, G. B. Pelletier, J. Genest Jr, R. Cartier, Y. Leclerc, and L. C. Pelletier Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation Ann. Thorac. Surg., February 1, 1994; 57(2): 353 - 356. [Abstract] [PDF]